Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Surgery · MOULTON, AL · NPI 1679523757
Verified facts
CMS Open Payments records show Rex C Tuckier, D.O. received $15.96 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.96 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $15.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 958 | 58 |
| Furosemide | Furosemide | 850 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 671 | 75 |
| Eliquis | Apixaban | 595 | 70 |
| Donepezil Hcl | Donepezil Hcl | 450 | 26 |
| Omeprazole | Omeprazole | 446 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 424 | 46 |
| Gabapentin | Gabapentin | 414 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 46 |
| Torsemide | Torsemide | 321 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 290 | 37 |
| Allopurinol | Allopurinol | 283 | 18 |
| Metformin Hcl | Metformin Hcl | 279 | 29 |
| Carvedilol | Carvedilol | 252 | 26 |
| Lisinopril | Lisinopril | 237 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 25 |
| Aptiom | Eslicarbazepine Acetate | 211 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 199 | 14 |
| Losartan Potassium | Losartan Potassium | 193 | 20 |
| Risperidone | Risperidone | 193 | suppressed |
| Trulicity | Dulaglutide | 168 | 11 |
| Buspirone Hcl | Buspirone Hcl | 166 | 17 |
| Mirtazapine | Mirtazapine | 157 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 24 |
| Trazodone Hcl | Trazodone Hcl | 150 | 20 |
| Tramadol Hcl | Tramadol Hcl | 149 | 16 |
| Farxiga | Dapagliflozin Propanediol | 135 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | suppressed |
| Sucralfate | Sucralfate | 126 | 17 |
| Entresto | Sacubitril/Valsartan | 120 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 20 |
| Xarelto | Rivaroxaban | 116 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 14 |
| Clonidine | Clonidine | 106 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | suppressed |
| Olanzapine | Olanzapine | 103 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 99 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 53 |
| Sertraline Hcl | Sertraline Hcl | 98 | 21 |
| Memantine Hcl | Memantine Hcl | 94 | 14 |
| Famotidine | Famotidine | 90 | 26 |
| Alprazolam | Alprazolam | 89 | suppressed |
| Meloxicam | Meloxicam | 89 | 17 |
| Phenytoin | Phenytoin | 88 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | suppressed |
| Spironolactone | Spironolactone | 87 | 19 |
| Methocarbamol | Methocarbamol | 82 | suppressed |
| Levofloxacin | Levofloxacin | 80 | 46 |
| Diltiazem Hcl | Diltiazem Hcl | 78 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 15 |
| Divalproex Sodium | Divalproex Sodium | 77 | suppressed |
| Azithromycin | Azithromycin | 75 | 35 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 75 | suppressed |
| Baclofen | Baclofen | 72 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 72 | suppressed |
| Lorazepam | Lorazepam | 71 | 19 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 68 | 67 |
| Levetiracetam | Levetiracetam | 67 | suppressed |
| Prednisone | Prednisone | 67 | 12 |
| Digoxin | Digoxin | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | suppressed |
| Bumetanide | Bumetanide | 64 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Simvastatin | Simvastatin | 55 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 52 | 52 |
| Albuterol Sulfate | Albuterol Sulfate | 51 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 11 |
| Phenobarbital | Phenobarbital | 49 | suppressed |
| Acetylcysteine | Acetylcysteine | 47 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Fentanyl | Fentanyl | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Nyamyc | Nystatin | 41 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Metolazone | Metolazone | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Silodosin | Silodosin | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 14 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.96 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error